Synthtrix Pharmalabs (India) Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 26-06-2024
- Paid Up Capital ₹ 4.00 Cr
as on 26-06-2024
- Company Age 14 Year, 10 Months
- Last Filing with ROC 31 Mar 2014
- Open Charges ₹ 15.50 Cr
as on 26-06-2024
About Synthtrix Pharmalabs (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2014. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 4.00 Cr.
The company currently has active open charges totaling ₹15.50 Cr.
Vasu Sabbella, Srirama Dwarampudi, and Srinivasa Medapati serve as directors at the Company.
- CIN/LLPIN
U24232AP2009PTC066297
- Company No.
066297
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Dec 2009
- Date of AGM
30 Sep 2014
- Date of Balance Sheet
31 Mar 2014
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Synthtrix Pharmalabs (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Srirama Dwarampudi  | Managing Director | 16-Dec-2009 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vasu Sabbella | Director | Current | |
| Srinivasa Medapati | Director | 16-Dec-2009 | Current |
Financial Performance and Corporate Structure Insights of Synthtrix Pharmalabs (India).
Enhance accessibility to Synthtrix Pharmalabs (India)'s financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Synthtrix Pharmalabs (India)?
Unlock access to Synthtrix Pharmalabs (India)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Syndicate Bank Creation Date: 24 Nov 2014 | ₹8.50 Cr | Open |
State Bank Of India Creation Date: 19 Mar 2011 | ₹7.00 Cr | Open |
How Many Employees Work at Synthtrix Pharmalabs (India)?
Synthtrix Pharmalabs (India) has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synthtrix Pharmalabs (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synthtrix Pharmalabs (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
